Novo, Nordisk
26.03.2026 – 03:56:40 | boerse-global.de
Novo Nordisk Slashes U.S. Drug Prices in Competitive Countermove – Foto: über boerse-global.de
In a strategic shift acknowledging intensified rivalry, Novo Nordisk has announced it will cut the U.S. list prices for its flagship drugs Ozempic and Wegovy by approximately half. Effective January 1, 2027, both medications are slated to be priced at around $675 per month. This decisive pricing action by the Danish pharmaceutical giant is a direct response to eroding market share in the lucrative GLP-1 therapy sector, where competitor Eli Lilly has gained significant ground.
Financial Positioning and Shareholder Returns
Novo Nordisk’s shares are currently trading near their 52-week low, valued at roughly eleven times the earnings per share anticipated for 2026. This represents a notable discount compared to its historical valuation multiples. The company is emphasizing capital returns to shareholders through a dividend yield of approximately 5% and an ongoing share repurchase initiative. This buyback program is authorized for up to 15 billion Danish kroner, with a segment of up to 3.8 billion kroner targeted for completion by May 4, 2026. The continuation of the program beyond March 26 is pending approval at the upcoming annual general meeting.
Eli Lilly’s Market Dominance Triggers Response
The catalyst for the price reduction is a substantial change in market dynamics. By the end of 2025, Novo Nordisk’s share of the U.S. GLP-1 market had fallen below 40%. Eli Lilly now commands over 60% of this segment. The price cuts—reducing Wegovy from about $1,350 to $675 and Ozempic from around $935 to $675—are designed to incentivize employers and insurance providers to broaden coverage. The strategic goal is to improve patient access and recapture lost market territory.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Pipeline Development Aims to Diversify Portfolio
Alongside its pricing strategy, Novo Nordisk is advancing its clinical pipeline to reduce reliance on its current semaglutide-based products. Recent regulatory and clinical milestones provide a second pillar for its strategy. On March 19, the U.S. FDA approved Wegovy HD, a higher-dose 7.2 mg formulation. Clinical trials for this version demonstrated an average weight reduction of 20.7%. Shortly after, on March 25, the company released Phase 2 data for its triple-agonist candidate, UBT251. In patients with type 2 diabetes, the treatment reduced HbA1c levels by up to 2.16 percentage points after 24 weeks.
Ad
Novo Nordisk Stock: New Analysis – 26 March
Fresh Novo Nordisk information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.
Read our updated Novo Nordisk analysis…
So schätzen Börsenprofis die Aktie Novo ein. Verpasse keine Chance mehr.
Ob Chancen, Risiken oder neue Signale zur Aktie Novo: trading-notes liefert dir seit 2005 dreimal pro Woche verlässliche Aktien-Impulse zu diesem und vielen weiteren spannenden Aktien-Werten – dreimal pro Woche kostenlos per E-Mail.
Für. Immer. Kostenlos.
DK0062498333 | NOVO | boerse | 68989065 |